{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 38,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a map of the US as a background element, likely to denote the geographic scope of the market sizing.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/24",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.615,
        "y": 0.115
      },
      "kind": "callout",
      "text": "Ovarian Cancer Market: ~$1.8B in 2022, expected CAGR growth ~23.5%; ~233,000 women in the US currently; 70-80% will relapse",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39c3e786-2498-4fc4-b3bb-f81a21c3dd21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.55,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f705da44-620b-4bb3-bb38-42af2eef62b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.06,
        "y": 0.02
      },
      "kind": "list",
      "text": "Ovarian Cancer; Non-Small Cell Lung Cancer; Additional revenue drivers: Re-treatment, Front-Line therapy, Additional Indications, i.e.: Small Cell Lung Cancer, Pancreatic Cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8a6aa86-5569-47d4-9fe6-ac925462d704",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.585,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Drivers of Market Penetration: The Phase 3 population is a broad category of patients with significant unmet medical need, including those excluded from other therapies or trials.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d646d642-8525-4173-adc4-c3d840d7deb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.14,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Polaris Market Research; 2. NIH Ovarian Cancer Fact Sheet",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d812d963-0977-4412-9e2d-170cd5330acb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (US)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b56be0b-6a79-4c52-a78a-fdb97e7a8886",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f1c5e2a7-c1a9-448f-a6b8-c925aaa816f5",
      "evidence": "list/bullet: Ovarian Cancer; Non-Small Cell Lung Cancer; Additional revenue drivers: Re-treatment, Front-Line therapy, Additional Indications, i.e.: Small Cell Lung Cancer, Pancreatic Cancer",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 24,
      "beatId": "b53412dd-e008-4b17-91c3-2cfcb87e9444",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The presentation provides an estimate of the commercial opportunity for Olvi-Vec, highlighting its potential market size.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}